

Figure S1: Cochrane risk of bias graph, illustrating the proportion of studies within each category of risk for each domain.




Figure S2: Funnel Plot for assessing publication bias: Overall placebo effect (N=25).




Figure S3: Funnel Plot for assessing publication bias: Overall placebo effect excluding two outlier studies (2,3) (N=23)




Figure S4: Forest plot for treatment response to active intervention (N = 25). CI: Confidence Interval

## References

1. Akhondzadeh S, Tajdar H, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Shabstari OL, *et al.* A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. *Child Psychiatry Hum Dev* 2008; 39:237-245.
2. Akhondzadeh S, Fallah J, Mohammadi MR, Imani R, Mohammadi M, Salehi B, *et al.* Double-blind placebo-controlled trial of pentoxifylline added to risperidone: Effects on aberrant behavior in children with autism. *Prog Neuropsychopharmacol Biol Psychiatry* 2010; 34:32-36.
3. Asadabadi M, Mohammadi MR, Ghanizadeh A, Modabbernia A, Ashrafi M, Hassanzadeh E, *et al.* Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: A randomized, double-blind, placebo-controlled trial. *Psychopharmacology* 2013; 225:51-59.
4. Bent S, Bertoglio K, Ashwood P, Bostrom A, Hendren RL. A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder. *J Autism Dev Disord* 2011; 41:545-554.
5. Bent S, Hendren RL, Zandi T, Law K, Choi JE, Widjaja F, *et al.* Internet-based, randomized, controlled trial of omega-3 fatty acids for hyperactivity in autism. *J Am Acad Child Adolesc Psychiatry* 2014; 53:658-666.
6. Fahmy SF, El-Hamamsy MH, Zaki OK, Badary OAL-Carnitine supplementation improves the behavioral symptoms in autistic children. *Research in Autism Spectrum Disorders* 2013; 7:159-166.
7. Ghaleiha A, Asadabadi M, Mohammadi MR, Shahei M, Tabrizi M, Hajiaghaee R, *et al.* Memantine as adjunctive treatment to risperidone in children with autistic disorder: A randomized, double-blind, placebo-controlled trial. *Int J Neuropsychopharmacol* 2013a; 16:783-789.
8. Ghaleiha A, Mohammadi E, Mohammadi MR, Farokhnia M, Modabbernia A, Yekehtaz H, *et al.* Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: A double-blind, placebo-controlled, randomized trial. *Pediatric Drugs* 2013b; 15:505-514.

9. Ghaleiha A, Ghyasvand M, Mohammadi M-R, Farokhnia M, Yadegari N, Tabrizi M, *et al.* Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial. *J Psychopharmacol (Oxf)* 2014; 28:677-685.
10. Ghanizadeh A, Moghimi-Sarani E. A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders. *BMC Psychiatry* 2013; 13:196.
11. Hardan AY, Fung LK, Libove RA, Obukhanych TV, Nair S, Herzenberg LA, *et al.* A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. *Biol Psychiatry* 2012; 71:956-961.
12. Hasanzadeh E, Mohammadi MR, Ghanizadeh A, Rezazadeh SA, Tabrizi M, Rezaei F, *et al.* A double-blind placebo controlled trial of Ginkgo biloba added to risperidone in patients with autistic disorders. *Child Psychiatry Hum Dev* 2012; 43:674-682.
13. Hellings JA, Weckbaugh M, Nickel EJ, Cain SE, Zarccone JR, Reese RM, *et al.* A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. *J Child Adolesc Psychopharmacol* 2005; 15:682-692.
14. Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S, *et al.* A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. *Neuropsychopharmacology* 2005; 30:582-589.
15. Hollander E, Chaplin W, Soorya L, Wasserman S, Novotny S, Rusoff J, *et al.* Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. *Neuropsychopharmacology* 2010; 35:990-998.
16. Kent J, Kushner S, Ning X, Karcher K, Ness S, Aman M, *et al.* Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study. *J Autism Dev Disord* 2013; 43:1773-1783.

17. King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, *et al.* Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autism. *Arch Gen Psychiatry* 2009; 66:583-590
18. Klaiman C, Huffman L, Masaki L, Elliott GR. Tetrahydrobiopterin as a treatment for autism spectrum disorders: A double-blind, placebo-controlled trial. *J Child Adolesc Psychopharmacol* 2013; 23:320-328.
19. Lemonnier E, Degrez C, Phelep M, Tyzio R, Josse F, Grandgeorge M, *et al.* A randomised controlled trial of bumetanide in the treatment of autism in children. *Translational Psychiatry* 2012; 2:e202.
20. Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, *et al.* A Placebo-Controlled, Fixed-Dose Study of Aripiprazole in Children and Adolescents With Irritability Associated With Autistic Disorder. *J Am Acad Child Adolesc Psychiatry* 2009; 48:1110-1119.
21. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, *et al.* Risperidone in children with autism and serious behavioral problems. *N Engl J Med* 2009; 347:314-321.
22. Mohammadi MR, Yadegari N, Hassanzadeh E, Farokhnia M, Yekehtaz H, Mirshafiee O, *et al.* Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: A 10-week randomized study. *Clin Neuropharmacol* 2013; 36:179-184.
23. Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: Randomized, placebo-controlled, double-blind study. *J Child Neurol* 2006; 21:450-455.
24. Rezaei V, Mohammadi MR, Ghanizadeh A, Sahraian A, Tabrizi M, Rezazadeh SA, *et al.* Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 2010; 34:1269-1272.



25. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, *et al.* Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and Other pervasive developmental disorders. *Pediatrics* 2004; 114:e634-e641.